Analysis of families with germline p53 mutations shows that the mutant p53 allele behaves as a dominant oncogene at the genetic level, although it behaves as a recessive oncogene at the cellular level, since tumours invariably show mutation or loss of both wild-type alleles. At the biochemical level it is possible that some clinically important mutant p53 proteins may be carcinogenic through a dominant mechanism. We show that p53 mutants can be readily classified according to their dominant potential using a simple yeast functional assay. Wild-type p53 is constitutively expressed from a TRP1 vector, p53 mutants are expressed from an otherwise identical LEU2 vector and net transcriptional activity is scored using an ADE2-based reporter. Twenty seven p53 mutants were tested: 19 were recessive, i.e. gave white colonies, and eight showed dominant activity, i.e. gave pink/red colonies. This simple assay should facilitate studies on p53 dominance.
p53 alleles inactivated by missense mutations are seen iñ 50% of all human tumours (1, 2) . Tumour-derived mutants are unable to function as sequence-specific transcription factors, generally because they contain mutations in the DNA binding domain which reduce the affinity for DNA (3, 4) . The high level of p53 protein commonly seen in tumours probably reflects the presence of a persistent p53 activating signal and loss of the mdm2-induced p53 degradation feedback loop (5,6). In a normal cell p53 activation leads to cell cycle arrest or apoptosis, but in a tumour containing mutant p53 the cells can continue to divide because mutant p53 is unable to transactivate its target genes. While this abortive activation/ impaired degradation model provides a satisfactory explanation for the high level p53 expression seen in tumours (5,6), it does not rule out the possibility that a selective growth advantage may be conferred by mutated p53 proteins, either because dominant inhibition of wild-type protein could facilitate progression from the heterozygous to the homozygous mutant state or because the mutant protein has a novel growth promoting activity (7) . Although superficially similar, there is an important biological distinction between these two models, since the former implies only loss of p53 function as a transcription factor, whereas the latter suggests that mutants have gained new functions.
Tumour development is marked by a long period of coexistence of wild-type and mutant protein in the same cell, either following an initial somatic mutagenic event or from birth in the case of germline mutations (2) . Since p53 exists as a stable tetramer in the cell (8) and since in most cases both alleles are equally expressed and equally stable, heterozygous mutant cells should contain a mixture of wild-type, mixed and mutant tetramers in the ratio 1:14:1, provided the mutant protein is able to form oligomers with the wild-type. The extent to which p53 mutants really do abrogate wild-type p53 function in the heterozygous state is controversial and depends on the particular assay employed (4,9-12), but there is certainly the potential for strong dominant inhibition of wild-type p53 through tetramerization with mutant protein in heterozygous cells.
It is possible to classify p53 mutations into those that introduce adverse contacts and actively prevent DNA binding by changing residues that physically interact with DNA (contact mutants) and those that interfere with the orientation of the contact residues by changing the overall structure of the DNA binding domain (structural mutants) (8) . Since physiological p53 binding sites in genomic DNA frequently contain imperfect matches to the p53 consensus, some subunits of a tetramer frequently do not make a full set of bonds with DNA. Indeed, a difference in affinity between the various natural p53 targets has been described (13) . Hence, a reduction in the number of available protein contact sites is not a priori grounds for mixed tetramers being inactive in the cell. It has been shown that wild-type p53 can form stable tetramers with DNA contact mutant proteins and that mixed tetramers can bind specific DNA sequences. For example, mixed tetramers containing 248W mutant p53 bind DNA well (10) , which illustrates how a reduced affinity, due to loss of the four hydrogen bonds between Arg248 and the minor groove, need not detract from high affinity binding by remaining wild-type subunits in the tetramer, provided the mutant residue (tryptophan) can be accommodated in the structure.
Despite the fact that only one out of 16 tetramers in a heterozygous cell are fully wild-type, some studies have shown near normal p53 responses in heterozygous cells. This may partly reflect the ability of p53 to accumulate to high levels after activation, an effect which could negate even a substantial reduction in the starting level of wild-type tetramers. Many of the problems with mammalian studies derive from the difficulty of achieving stable low level p53 expression in a reproducibly defined genetic background and results are frequently clouded by concerns over the amount of p53 produced, which often far exceeds any relevant physiological level. For instance, differences with transcription assays and transformation assays probably reflect the fact that very small amounts of p53 give saturating levels of transcriptional activation, whilst CMV promoter-derived p53 overexpression is necessary for growth inhibition. Dominance is an important issue in transformation assays, where incoming p53 mutants must inactivate both resident wild-type alleles. A further problem with mammalian transfection studies is that it is difficult to achieve exactly equal expression of both alleles. This can be overcome by use of bicistronic vectors and studies using this approach have shown that wild-type p53 is generally dominant over mutant p53 (12) .
To get over some of the problems with mammalian studies we have modified the ADE2-based yeast p53 functional assay (14) to allow straightforward characterization of the dominance potential of p53 mutants. In this assay, human p53 cDNA is cloned by homologous recombination in vivo (gap repair) into a yeast expression vector. To determine whether the p53 clone can activate transcription, the yeast strain contains a transcription reporter ( Figure 1A) where the ADE2 gene is regulated by a p53-responsive promoter. With this system, wild-type p53 gives white colonies and mutant p53 gives red colonies. To test dominance, two p53 cDNA must be expressed together in the reporter strain. The existing expression vector has a LEU2 marker; a new p53 expression vector, named pTS76, was therefore constructed which is identical with the first but has a TRP1 marker. To do this, the 4.9 kb PvuI fragment (bp 2968-7964) containing the pADH1 wild-type p53 cDNA from pLS76 (15) was ligated to the 2.9 kb PvuI (19) . e Amino acid change never found, but this is a site of a known polymorphism.
fragment (bp 5973-1736) containing the CEN/ARS TRP1 region from pLS89 (16) . pTS76 was used to express wildtype p53, while different p53 mutants were expressed from pLS76-derived LEU2 vectors. The haploid strain yIG397 (MATa ade2-1 leu2-3,112 trp1-1 his3-11,15 can1-100, ura3-1 URA3 3xRGC::pCYC1::ADE2), containing the ADE2 reporter gene under p53 control, was transfected with equimolar amounts of both vectors by electroporation. Double transformants were selected on minimal plates lacking leucine and tryptophan but containing sufficient adenine (5 mg/l) for adenine auxotrophs to grow and turn red. Double transformant clones (Leu ϩ , Trp ϩ ) giving rise to white (Ade ϩ ) or pink/ red (Ade -) colonies were interpreted as expressing recessive ( Figure 1B) or dominant ( Figure 1C ) mutations respectively. Generally, Ͼ100 independent transformants were analysed and their phenotype was invariably homogeneous. A panel of p53 mutations obtained through application of the yeast p53 functional assay to the field of mutagenesis (17) was used to validate the dominance assay. This included 18 CCNU-induced and nine UV-induced mutants (Table I) . About 20% of the experimentally induced p53 mutants selected so far in yeast (19 out of 82) (17; unpublished data) contain base pair substitutions never found in human tumours or cell lines (18; EMBL database, May 13 1996, 5174 mutations entered). Such mutations, although completely inactive for transactivation (red colonies), are apparently not selected for in vivo during the carcinogenic process. This could reflect mutagen specificity, repair specificity or some biological activity of the mutants. In particular, if dominance plays an important part in vivo, one would not expect to see recessive mutations in tumours.
Dominance analysis revealed that all the CCNU-and UVinduced mutations not found in human tumours were indeed recessive (Table I) . Double transformants of eight out of the 17 mutants already found in tumours showed instead pink/red colonies and were considered dominant. However, colony size and staining intensity suggested the presence of a minimal wild-type p53 activity. All dominant mutants affected key amino acids that are essential for stabilization of the DNA binding surface of the p53 core domain or for direct interaction between p53 and DNA (19) .
Recently another selection scheme (URA3-based) for spontaneous dominant p53 mutations in yeast was described (20) . The analysis of that spectrum showed that p53 dominant mutations correlate well with mutational hotspots in human cancer. Only two out of the 41 dominant mutations described (20) have not been observed in tumours, a number significantly lower than that found by selecting mutants irrespective of their dominant phenotype (19 out of 82, P ϭ 0.01, Fisher's exact test) (17; unpublished data). The results with the ADE2 selection method are generally consistent with those obtained by the URA3-based selection. Dominant mutations were found only in the group of mutants already found in tumours (Table  I ; P ϭ 0.012, Fisher's exact test).
Selection for dominance thus may play a role in determining the mutation spectrum seen in human tumours. It should be noted, however, that this is not evidence for 'gain of function' in the sense of acquisition of novel biochemical activities favouring tumour cell growth, since it can be adequately explained by mutant-induced loss of function of the wild-type allele. The ability to classify mutants simply according to their dominant potential at the biochemical/cellular level should facilitate studies on Li-Fraumeni syndrome and tumour progression from the heterozygous to the homozygous state and it may in future provide important information to the clinician about the likelihood of response to chemotherapy and p53 gene therapy.
